185 related articles for article (PubMed ID: 34862715)
21. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
22. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
Yin Z; Mander AP; de Bono JS; Zheng H; Yap C
JCO Precis Oncol; 2024 Jan; 8():e2300441. PubMed ID: 38181316
[TBL] [Abstract][Full Text] [Related]
23. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
24. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
Lin R; Yuan Y
Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
[TBL] [Abstract][Full Text] [Related]
25. Phase I dose-escalation oncology trials with sequential multiple schedules.
Günhan BK; Weber S; Seroutou A; Friede T
BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
[TBL] [Abstract][Full Text] [Related]
26. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
27. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
Zhao D; Zhu J; Wang L
Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
[TBL] [Abstract][Full Text] [Related]
28. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
Chapple AG; Thall PF
Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806
[TBL] [Abstract][Full Text] [Related]
29. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
Takeda K; Zhu J; Li R; Yamaguchi Y
Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
[TBL] [Abstract][Full Text] [Related]
30. Monitoring late-onset toxicities in phase I trials using predicted risks.
Bekele BN; Ji Y; Shen Y; Thall PF
Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
[TBL] [Abstract][Full Text] [Related]
31. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
Li R; Takeda K; Rong A
Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
[TBL] [Abstract][Full Text] [Related]
32. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
Shi H; Cao J; Yuan Y; Lin R
Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
[TBL] [Abstract][Full Text] [Related]
33. Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses.
Chen X; Zhang J; Jiang L; Yan F
Stat Methods Med Res; 2023 Mar; 32(3):443-464. PubMed ID: 36217826
[TBL] [Abstract][Full Text] [Related]
34. Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity.
Xu Z; Lin X
Stat Methods Med Res; 2022 Mar; 31(3):534-548. PubMed ID: 34806915
[TBL] [Abstract][Full Text] [Related]
35. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Andrillon A; Biard L; Lee SM
J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
[TBL] [Abstract][Full Text] [Related]
36. Dose-finding design and benchmark for a right censored endpoint.
Andrillon A; Chevret S; Lee SM; Biard L
J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
[TBL] [Abstract][Full Text] [Related]
37. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials.
Zhou Y; Zhao Y; Cicconetti G; Mu Y; Yuan Y; Wang L; Penugonda S; Salman Z
Pharm Stat; 2023 Mar; 22(2):300-311. PubMed ID: 36333972
[TBL] [Abstract][Full Text] [Related]
38. A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
[TBL] [Abstract][Full Text] [Related]
39. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
40. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
